The Funds managed by PZU OFE increased their stake in BRASTER to 5.03%; BRASTER is a company based in Warsaw which, as soon as this year, plans to place on the Polish market a revolutionary device supporting breast cancer self-examination. PZU OFE is yet another investor that has recently increased its stake in the Company.
The increase in the stock came as a result of a private stock offering in mid-June, in which the Company acquired PLN 7.6 million in order to finance the activities related to the commercialisation of Braster. Before the deal, PZU OFE’s portfolio included 4.41% of the Company’s shares. Over the last weeks, also the Funds managed by Investors TFI increased their stake in BRASTER, exceeding the 5% threshold. Following the buy transaction, their stake increased from 4.92% to 5.27%.
"We are very glad that our investors can see our business potential and appreciate the consistent implementation of our strategy, which is manifested by the increased stake in our Company," commented Marcin Halicki, President of the Management Board of BRASTER S.A.
According to publicly available data, apart from funds of PZU OFE and Investors TFI, other shareholders with over 5% stake in BRASTER include Funds controlled by mBank S.A., Ipopema Towarzystwo Funduszy Inwestycyjnych S.A. (Ipopema TFI), as well as Tadeusz Wesołowski, PhD, who is an investor engaging in listed companies from the medical and biotechnology sector.
Braster will be the world’s first device supporting early detection of breast cancer, addressing directly women. The commercialisation work is going according to plan and the Company plans to place the device on the Polish market in autumn. If the product is successfully commercialised and placed on the Polish and international markets, the BRASTER business will start to generate considerable revenues, which will strategically influence the future financial results of the Company.